title: Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
abstract: Recombinant factor VII with residue 217 (chymotrypsinogen numbering system) converted to alanine (VIIQ217A), glutamic acid (VIIQ217E), or glycine (VIIQ217G) was characterized. In a prothrombin time assay, VIIQ217E demonstrated 100%, VIIQ217A 15%, and VIIQ217G <1% clotting activities relative to wild-type VII. Binding of VIIQ217A and VIIQ217G to TF was comparable to that of wild-type VII to TF. All the variants were readily activated by factor Xa. Autoactivation in the presence of TF was efficient with VIIQ217E, slow with VIIQ217A, but undetected with VIIQ217G. Relative to wild-type VII added at the same concentration, VIIQ217E had no effect on the PT of normal plasma, whereas VIIQ217A slightly and VIIQ217G dramatically prolonged the clotting time in a dose-dependent manner. Activation of macromolecular substrates paralleled this functional inhibition. The k(cat)/K(M) values for factor X activation in the presence of TF were 2.4 for VIIaQ217E as compared to 1.9 (M(-)(1) s(-)(1) x 10(7)) for wild-type VIIa, 1.57 for VIIaQ217A, and 0.05 with VIIaQ217G. In comparison to wild-type VIIa, VIIaQ217E cleaved the chromogenic substrate S2765 (Z-D-Arg-Gly-Arg-pNA) with 10-fold higher k(cat). Analysis of the interactions with the inhibitors TFPI and antithrombin III demonstrated that VIIaQ217A but not VIIaQ217E or VIIaQ217G was inhibited less efficiently by TFPI either in the presence or in the absence of factor Xa. In contrast, VIIaQ217A association with antithrombin III in the presence of heparin was the fastest among the variants with a second-order rate constant of 2.31 (x10(3) M(-)(1) min(-)(1)), as compared to 0.47 and 1.47 for VIIaQ217E and wild-type VIIa, respectively. Our results demonstrate that residue Q(217) is important in regulating substrate and, more importantly, inhibitor recognition by VIIa.
authors.affiliation: Graduate Institute of Medical Technology, Department of Laboratory of Medical Sciences, College of Medicine, National Taiwan University, Taipei, ROC.
authors.forename: Y J
authors.initials: YJ
authors.lastname: Chang
authors.forename: N
authors.initials: N
authors.lastname: Hamaguchi
authors.forename: S C
authors.initials: SC
authors.lastname: Chang
authors.forename: W
authors.initials: W
authors.lastname: Ruf
authors.forename: M C
authors.initials: MC
authors.lastname: Shen
authors.forename: S W
authors.initials: SW
authors.lastname: Lin
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics*; D000925:Anticoagulants / Q000378:metabolism*; D000990:Antithrombin III / Q000378:metabolism; D001780:Blood Coagulation Tests; D002384:Catalysis; D002460:Cell Line; D002863:Chromogenic Compounds / Q000378:metabolism; D005167:Factor VII / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D005170:Factor X / Q000378:metabolism; D015951:Factor Xa / Q000502:physiology; D005786:Gene Expression Regulation; D005973:Glutamine / Q000235:genetics*; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D046911:Macromolecular Substances; D016297:Mutagenesis, Site-Directed; D011485:Protein Binding / Q000235:genetics; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D013379:Substrate Specificity / Q000235:genetics; D013925:Thromboplastin / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D014162:Transfection
chemical_list: D000925:Anticoagulants; D002863:Chromogenic Compounds; D008074:Lipoproteins; D046911:Macromolecular Substances; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D005973:Glutamine; D000990:Antithrombin III; D005167:Factor VII; D005170:Factor X; D013925:Thromboplastin; D015951:Factor Xa